 Jordan Jacobelli
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 22 | 2022 | 1737 | 3.470 |
Why?
| | Cell Movement | 18 | 2021 | 869 | 2.790 |
Why?
| | Nonmuscle Myosin Type IIA | 5 | 2016 | 8 | 2.100 |
Why?
| | Actins | 7 | 2022 | 381 | 1.610 |
Why?
| | Cell Adhesion Molecules | 4 | 2022 | 168 | 1.290 |
Why?
| | Microfilament Proteins | 2 | 2022 | 126 | 1.280 |
Why?
| | Autoimmunity | 5 | 2021 | 813 | 1.260 |
Why?
| | Phosphoproteins | 2 | 2022 | 298 | 1.170 |
Why?
| | Lymphocyte Activation | 12 | 2022 | 1037 | 1.070 |
Why?
| | Transendothelial and Transepithelial Migration | 2 | 2017 | 29 | 0.990 |
Why?
| | Lymph Nodes | 4 | 2018 | 419 | 0.910 |
Why?
| | Actin-Related Protein 2-3 Complex | 2 | 2021 | 8 | 0.900 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2022 | 688 | 0.780 |
Why?
| | Cell Adhesion | 8 | 2017 | 432 | 0.770 |
Why?
| | Antigen-Presenting Cells | 7 | 2021 | 150 | 0.690 |
Why?
| | Molecular Imaging | 1 | 2018 | 50 | 0.580 |
Why?
| | Cell Communication | 7 | 2014 | 280 | 0.560 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2018 | 127 | 0.560 |
Why?
| | Interleukin-4 | 1 | 2018 | 206 | 0.550 |
Why?
| | Immunological Synapses | 5 | 2022 | 18 | 0.520 |
Why?
| | Leukemia, Experimental | 1 | 2016 | 27 | 0.520 |
Why?
| | Diabetes Mellitus, Type 1 | 7 | 2021 | 3256 | 0.490 |
Why?
| | Dendritic Cells | 6 | 2018 | 435 | 0.480 |
Why?
| | Mice | 24 | 2022 | 14872 | 0.470 |
Why?
| | Cell Nucleus | 2 | 2016 | 554 | 0.460 |
Why?
| | Animals | 32 | 2022 | 31710 | 0.450 |
Why?
| | Peripheral Tolerance | 1 | 2013 | 14 | 0.420 |
Why?
| | Islets of Langerhans | 4 | 2021 | 728 | 0.410 |
Why?
| | Gene Expression | 1 | 2018 | 1421 | 0.410 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 256 | 0.410 |
Why?
| | Inflammation | 2 | 2020 | 2480 | 0.400 |
Why?
| | Polymerization | 3 | 2022 | 119 | 0.400 |
Why?
| | B-Lymphocytes | 4 | 2021 | 766 | 0.340 |
Why?
| | Intercellular Adhesion Molecule-1 | 3 | 2009 | 154 | 0.330 |
Why?
| | CD11c Antigen | 3 | 2019 | 38 | 0.310 |
Why?
| | Phagocytes | 2 | 2021 | 90 | 0.310 |
Why?
| | Mice, Knockout | 5 | 2020 | 2570 | 0.300 |
Why?
| | Receptors, Antigen, T-Cell | 6 | 2014 | 615 | 0.300 |
Why?
| | Signal Transduction | 10 | 2019 | 4517 | 0.270 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3535 | 0.270 |
Why?
| | Antigens | 4 | 2021 | 318 | 0.270 |
Why?
| | Cytoskeletal Proteins | 2 | 2022 | 145 | 0.260 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2015 | 352 | 0.250 |
Why?
| | Mice, Inbred C57BL | 7 | 2021 | 4694 | 0.250 |
Why?
| | Brain | 1 | 2016 | 2371 | 0.230 |
Why?
| | Molecular Motor Proteins | 1 | 2004 | 33 | 0.220 |
Why?
| | Ovalbumin | 2 | 2015 | 161 | 0.220 |
Why?
| | Myosin Heavy Chains | 1 | 2004 | 177 | 0.210 |
Why?
| | Endothelial Cells | 2 | 2020 | 687 | 0.200 |
Why?
| | Lysophospholipids | 1 | 2022 | 65 | 0.190 |
Why?
| | Killer Cells, Natural | 5 | 2004 | 380 | 0.190 |
Why?
| | Immune Tolerance | 2 | 2021 | 323 | 0.190 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2021 | 43 | 0.190 |
Why?
| | Mice, Transgenic | 5 | 2021 | 1950 | 0.190 |
Why?
| | Vaccines, Conjugate | 1 | 2021 | 59 | 0.180 |
Why?
| | Cell Line | 3 | 2020 | 2637 | 0.180 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 93 | 0.180 |
Why?
| | Lymphatic System | 1 | 2020 | 12 | 0.180 |
Why?
| | Pneumococcal Infections | 1 | 2021 | 91 | 0.170 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2021 | 116 | 0.170 |
Why?
| | Phosphorylation | 7 | 2014 | 1569 | 0.170 |
Why?
| | Streptococcus pneumoniae | 1 | 2021 | 133 | 0.170 |
Why?
| | Adaptive Immunity | 1 | 2021 | 155 | 0.170 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 131 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2017 | 959 | 0.160 |
Why?
| | Antigen Presentation | 2 | 2013 | 188 | 0.160 |
Why?
| | Diabetes Mellitus, Experimental | 2 | 2021 | 160 | 0.150 |
Why?
| | Myosin Type II | 2 | 2015 | 10 | 0.150 |
Why?
| | Germinal Center | 1 | 2018 | 48 | 0.150 |
Why?
| | Integrin alpha4 | 1 | 2017 | 6 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2018 | 257 | 0.140 |
Why?
| | Cells, Cultured | 7 | 2016 | 3886 | 0.140 |
Why?
| | T-Lymphocyte Subsets | 2 | 2012 | 383 | 0.140 |
Why?
| | Microscopy | 1 | 2018 | 125 | 0.140 |
Why?
| | Cellular Microenvironment | 2 | 2014 | 78 | 0.130 |
Why?
| | Chemotaxis | 1 | 2017 | 130 | 0.130 |
Why?
| | Nuclear Lamina | 1 | 2016 | 10 | 0.130 |
Why?
| | Mononuclear Phagocyte System | 1 | 2016 | 12 | 0.130 |
Why?
| | Cytoskeleton | 3 | 2022 | 176 | 0.130 |
Why?
| | Spleen | 2 | 2015 | 487 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2016 | 61 | 0.130 |
Why?
| | HIV-1 | 1 | 2021 | 768 | 0.130 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 1 | 2015 | 33 | 0.120 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 2 | 2013 | 66 | 0.120 |
Why?
| | Software | 1 | 2018 | 530 | 0.110 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 685 | 0.110 |
Why?
| | Immunoblotting | 2 | 2016 | 283 | 0.110 |
Why?
| | Gene Knockout Techniques | 1 | 2013 | 98 | 0.110 |
Why?
| | Alum Compounds | 1 | 2013 | 22 | 0.110 |
Why?
| | Vaccination | 1 | 2021 | 1204 | 0.110 |
Why?
| | Mice, Inbred NOD | 3 | 2021 | 555 | 0.100 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 51 | 0.100 |
Why?
| | Muramidase | 1 | 2012 | 72 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 97 | 0.100 |
Why?
| | Flow Cytometry | 1 | 2016 | 1083 | 0.100 |
Why?
| | Autoantigens | 1 | 2014 | 396 | 0.100 |
Why?
| | Adjuvants, Immunologic | 1 | 2013 | 206 | 0.100 |
Why?
| | Immune System | 1 | 2013 | 172 | 0.090 |
Why?
| | Immunoglobulin E | 1 | 2012 | 314 | 0.090 |
Why?
| | Immunity, Cellular | 1 | 2013 | 248 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2018 | 1701 | 0.090 |
Why?
| | Neutrophils | 1 | 2016 | 1176 | 0.090 |
Why?
| | Interleukin-2 | 2 | 2004 | 413 | 0.090 |
Why?
| | Humans | 19 | 2022 | 114709 | 0.090 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2003 | 395 | 0.080 |
Why?
| | Integrin beta1 | 2 | 2000 | 17 | 0.080 |
Why?
| | Cell Surface Extensions | 1 | 2008 | 11 | 0.080 |
Why?
| | Cell Shape | 1 | 2008 | 54 | 0.080 |
Why?
| | GTP Phosphohydrolases | 1 | 2008 | 65 | 0.080 |
Why?
| | Neoplasms | 1 | 2022 | 2097 | 0.080 |
Why?
| | Transfection | 2 | 2009 | 866 | 0.080 |
Why?
| | Microscopy, Confocal | 1 | 2009 | 304 | 0.070 |
Why?
| | Receptors, Chemokine | 2 | 2006 | 44 | 0.070 |
Why?
| | Cysteine Endopeptidases | 1 | 2007 | 60 | 0.070 |
Why?
| | Apoptosis | 1 | 2016 | 2363 | 0.070 |
Why?
| | Protozoan Proteins | 1 | 2007 | 62 | 0.070 |
Why?
| | Protease Inhibitors | 1 | 2007 | 97 | 0.070 |
Why?
| | Multigene Family | 1 | 2007 | 190 | 0.070 |
Why?
| | Receptors, IgG | 2 | 2004 | 67 | 0.070 |
Why?
| | DNA | 1 | 2013 | 1352 | 0.070 |
Why?
| | Intracellular Fluid | 1 | 2005 | 27 | 0.060 |
Why?
| | Extracellular Fluid | 1 | 2005 | 30 | 0.060 |
Why?
| | Aging | 1 | 2015 | 1618 | 0.060 |
Why?
| | Chemokines | 1 | 2006 | 216 | 0.060 |
Why?
| | Intercellular Junctions | 1 | 2005 | 33 | 0.060 |
Why?
| | Membrane Microdomains | 1 | 2005 | 32 | 0.060 |
Why?
| | Wiskott-Aldrich Syndrome | 1 | 2004 | 2 | 0.060 |
Why?
| | Female | 9 | 2021 | 59571 | 0.060 |
Why?
| | Male | 5 | 2021 | 55667 | 0.060 |
Why?
| | Lung | 1 | 2016 | 3561 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 435 | 0.050 |
Why?
| | Evolution, Molecular | 1 | 2007 | 430 | 0.050 |
Why?
| | Interferon-gamma | 2 | 2014 | 719 | 0.050 |
Why?
| | rac GTP-Binding Proteins | 1 | 2003 | 34 | 0.050 |
Why?
| | Integrins | 1 | 2003 | 79 | 0.050 |
Why?
| | Endothelium | 1 | 2003 | 111 | 0.050 |
Why?
| | Inositol 1,4,5-Trisphosphate Receptors | 1 | 2022 | 26 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2022 | 29 | 0.050 |
Why?
| | Chemokine CCL21 | 2 | 2015 | 13 | 0.050 |
Why?
| | Receptors, CCR7 | 2 | 2015 | 24 | 0.050 |
Why?
| | CD11 Antigens | 1 | 2021 | 30 | 0.050 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 9 | 0.050 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 25 | 0.050 |
Why?
| | Tyrosine | 4 | 2004 | 214 | 0.040 |
Why?
| | Neoplasms, Experimental | 1 | 2021 | 151 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2021 | 119 | 0.040 |
Why?
| | Proteins | 2 | 2004 | 908 | 0.040 |
Why?
| | Receptors, Fibronectin | 1 | 2000 | 6 | 0.040 |
Why?
| | Asthma | 1 | 2012 | 2029 | 0.040 |
Why?
| | Adenine | 1 | 2021 | 219 | 0.040 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2000 | 56 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2000 | 195 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 309 | 0.040 |
Why?
| | Interleukin-8 | 1 | 2000 | 237 | 0.040 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1999 | 53 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 1998 | 45 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2000 | 278 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 126 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2000 | 276 | 0.040 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 172 | 0.040 |
Why?
| | Cell Membrane | 2 | 2012 | 680 | 0.030 |
Why?
| | Urinary Bladder Neoplasms | 1 | 1999 | 196 | 0.030 |
Why?
| | Lamin Type A | 1 | 2016 | 40 | 0.030 |
Why?
| | Mice, Nude | 2 | 2013 | 630 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 1998 | 367 | 0.030 |
Why?
| | Chemokine CCL19 | 1 | 2015 | 6 | 0.030 |
Why?
| | Cathepsins | 1 | 2015 | 22 | 0.030 |
Why?
| | Lymphocyte Function-Associated Antigen-1 | 2 | 2006 | 31 | 0.030 |
Why?
| | Cadaver | 1 | 2016 | 299 | 0.030 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2015 | 70 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2015 | 267 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3004 | 0.030 |
Why?
| | Enzyme Activation | 3 | 2000 | 785 | 0.030 |
Why?
| | Receptor Cross-Talk | 1 | 2013 | 20 | 0.030 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2012 | 41 | 0.030 |
Why?
| | Disease Progression | 1 | 2019 | 2381 | 0.030 |
Why?
| | Cytokinesis | 1 | 2013 | 46 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2012 | 195 | 0.030 |
Why?
| | Focal Adhesion Kinase 2 | 2 | 2003 | 3 | 0.020 |
Why?
| | Aerosols | 1 | 2012 | 150 | 0.020 |
Why?
| | Cell Separation | 1 | 2012 | 291 | 0.020 |
Why?
| | Lipid Bilayers | 1 | 2012 | 99 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2012 | 641 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2012 | 396 | 0.020 |
Why?
| | Fluorescence | 1 | 2010 | 148 | 0.020 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2008 | 130 | 0.020 |
Why?
| | Myosins | 1 | 2008 | 126 | 0.020 |
Why?
| | Septins | 1 | 2008 | 40 | 0.020 |
Why?
| | Autoantibodies | 1 | 2015 | 1349 | 0.020 |
Why?
| | Adult | 2 | 2021 | 30561 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2021 | 9089 | 0.020 |
Why?
| | Trypanosoma cruzi | 1 | 2007 | 23 | 0.020 |
Why?
| | RNA Interference | 1 | 2008 | 433 | 0.020 |
Why?
| | Stress, Mechanical | 1 | 2008 | 445 | 0.020 |
Why?
| | Chemokines, CC | 1 | 2006 | 28 | 0.020 |
Why?
| | Down-Regulation | 1 | 2008 | 594 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2320 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 271 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10471 | 0.020 |
Why?
| | Mice, Inbred Strains | 1 | 2006 | 396 | 0.020 |
Why?
| | Ligands | 1 | 2006 | 562 | 0.010 |
Why?
| | Wiskott-Aldrich Syndrome Protein | 1 | 2004 | 2 | 0.010 |
Why?
| | cdc42 GTP-Binding Protein | 1 | 2004 | 24 | 0.010 |
Why?
| | Antigens, CD | 1 | 2006 | 442 | 0.010 |
Why?
| | Chromosomes, Human, X | 1 | 2004 | 60 | 0.010 |
Why?
| | Integrin alpha4beta1 | 1 | 2003 | 6 | 0.010 |
Why?
| | Genetic Linkage | 1 | 2004 | 294 | 0.010 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2003 | 35 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2007 | 1982 | 0.010 |
Why?
| | Adolescent | 1 | 2021 | 17854 | 0.010 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 133 | 0.010 |
Why?
| | Proline | 1 | 2003 | 72 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2785 | 0.010 |
Why?
| | Thrombocytopenia | 1 | 2004 | 177 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1016 | 0.010 |
Why?
| | Antibodies | 1 | 2004 | 371 | 0.010 |
Why?
| | Protein Binding | 1 | 2007 | 1890 | 0.010 |
Why?
| | Middle Aged | 1 | 2021 | 26740 | 0.010 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2000 | 19 | 0.010 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2000 | 43 | 0.010 |
Why?
| | CD18 Antigens | 1 | 2000 | 33 | 0.010 |
Why?
| | MAP Kinase Kinase 3 | 1 | 2000 | 4 | 0.010 |
Why?
| | Enzyme Induction | 1 | 2000 | 84 | 0.010 |
Why?
| | K562 Cells | 1 | 2000 | 73 | 0.010 |
Why?
| | p21-Activated Kinases | 1 | 2000 | 14 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 113 | 0.010 |
Why?
| | Fibronectins | 1 | 2000 | 108 | 0.010 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 1998 | 10 | 0.010 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 1998 | 10 | 0.010 |
Why?
| | GRB2 Adaptor Protein | 1 | 1998 | 12 | 0.010 |
Why?
| | Retroviridae | 1 | 1999 | 90 | 0.010 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2000 | 260 | 0.010 |
Why?
| | Transplantation, Heterologous | 1 | 1999 | 181 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 1998 | 164 | 0.010 |
Why?
| | Cross-Linking Reagents | 1 | 1998 | 181 | 0.010 |
Why?
| | Genetic Vectors | 1 | 1999 | 289 | 0.010 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1999 | 172 | 0.010 |
Why?
| | Genetic Therapy | 1 | 1999 | 257 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 1999 | 850 | 0.010 |
Why?
| | Immunotherapy | 1 | 1999 | 474 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1999 | 1313 | 0.010 |
Why?
| | RNA, Messenger | 1 | 1999 | 2553 | 0.010 |
Why?
| | Infant | 1 | 2004 | 7968 | 0.010 |
Why?
| | Child, Preschool | 1 | 2004 | 9118 | 0.010 |
Why?
| | Child | 1 | 2004 | 18422 | 0.000 |
Why?
|
|
Jacobelli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|